BR100 Decreased By (-0.27%)
BR30 Decreased By (-0.01%)
KSE100 Decreased By (-0.24%)
KSE30 Decreased By (-0.28%)
AGHA 7.80 Decreased By ▼ -0.01 (-0.13%)
BECO 5.19 Decreased By ▼ -0.02 (-0.38%)
BML 57.50 No Change ▼ 0.00 (0%)
BOP 33.80 Decreased By ▼ -0.23 (-0.68%)
CNERGY 10.01 Increased By ▲ 0.05 (0.5%)
CSIL 5.40 Increased By ▲ 0.09 (1.69%)
FCCL 54.54 Decreased By ▼ -0.16 (-0.29%)
FFL 16.69 No Change ▼ 0.00 (0%)
FNEL 1.25 Increased By ▲ 0.02 (1.63%)
KEL 7.39 Decreased By ▼ -0.01 (-0.14%)
KOSM 5.74 Decreased By ▼ -0.03 (-0.52%)
LOTCHEM 29.20 Decreased By ▼ -0.12 (-0.41%)
MLCF 93.39 Decreased By ▼ -0.97 (-1.03%)
NBP 202.75 Decreased By ▼ -0.30 (-0.15%)
NCPL 56.90 Decreased By ▼ -0.10 (-0.18%)
NPL 67.70 No Change ▼ 0.00 (0%)
OGDC 316.40 Increased By ▲ 0.56 (0.18%)
PACE 10.70 Increased By ▲ 0.06 (0.56%)
PAEL 43.25 Increased By ▲ 0.05 (0.12%)
PIBTL 16.74 No Change ▼ 0.00 (0%)
PPL 218.35 Decreased By ▼ -1.43 (-0.65%)
PRL 49.91 Increased By ▲ 0.72 (1.46%)
PTC 71.05 Increased By ▲ 0.52 (0.74%)
SSGC 28.00 Decreased By ▼ -0.25 (-0.88%)
TBL 9.80 Decreased By ▼ -0.06 (-0.61%)
TELE 8.77 Decreased By ▼ -0.02 (-0.23%)
TPL 18.00 Decreased By ▼ -0.24 (-1.32%)
TPLP 13.45 Increased By ▲ 0.18 (1.36%)
TREET 22.73 Increased By ▲ 0.01 (0.04%)
TRG 60.45 Increased By ▲ 0.31 (0.52%)
World

Hong Kong advisory panel approves China's Sinovac COVID-19 vaccine for emergency use

  • Hong Kong's government said in early February that it was exempting Chinese drug maker Sinovac from publishing results of its third phase clinical trials in medical journals due to the "urgency" for vaccination.
  • The city's Health Secretary Sophia Chan has the final decision on whether to approve the Sinovac vaccine.
Published Updated
By

HONG KONG: A Hong Kong government advisory panel on COVID-19 vaccines said on Tuesday it would recommend China's Sinovac vaccine for emergency use, a move that brings it a step closer to being formally greenlighted in the Asian financial hub.

Hong Kong's government said in early February that it was exempting Chinese drug maker Sinovac from publishing results of its third phase clinical trials in medical journals due to the "urgency" for vaccination.

The Pfizer/BioNTech vaccine - the first approved by Hong Kong's Health department - was required to have published results in a medical journal before being examined by the advisory panel.

The city's Health Secretary Sophia Chan has the final decision on whether to approve the Sinovac vaccine.

Comments

Comments are closed for this article.